|
Post by mango on Dec 10, 2020 20:32:05 GMT -5
We have three events taking place sometime next year.
—TreT FDA filing
—Sumatriptan Phase 1
—Clofazimine Phase 1
Some speculative plays for next year include:
—Tobramycin and/or Dornase Alfa advancement into Phase 1 or announcement(s) stating they will be initiated into Phase 1 in 2022.
—Second UT molecule
—New partnership
—RLS
—COVID
—International expansion update (India clinical trial, Australia, etc)
—Afrezza Peds Phase 3 start date announcement
What’s y’all’s thoughts on next year? I believe it will be an exciting year for the company and us shareholders.
|
|
|
Post by neil36 on Dec 10, 2020 20:55:30 GMT -5
Wishful thinking, but at some point it would be nice to get some surprise numbers from Brazil. Afrezza has been there for well over a year now and the only reported income is $900,000. I think most have mentally written it off. It would be a very pleasant surprise if it suddenly started contributing some decent (eight figure) revenues.
|
|
|
Post by akemp3000 on Dec 10, 2020 20:58:56 GMT -5
I agree. The transition from all or nothing with Afrezza to a potentially ever expanding pipeline that happens to include Afrezza has been interesting to say the least. I agree and hope 2021 is the year Technosphere and this company gets the attention it deserves.
|
|
|
Post by mango on Dec 10, 2020 21:23:18 GMT -5
I wonder how much of an impact COVID has had in Brazil in regards to Afrezza.
|
|
|
Post by peppy on Dec 10, 2020 21:34:47 GMT -5
I wonder how much of an impact COVID has had in Brazil in regards to Afrezza. The word is Venezuela is pretty COVID bad. Brazil population @ 209.5 million (2018) The governments are using COVID-19 to take the population numbers down. The rich in these countries have live in help. Aren't I susie sunshine.
|
|
|
Post by mytakeonit on Dec 10, 2020 22:31:33 GMT -5
How long has it been since we partnered with UTHR ? I doubt that it has been a year ... and that happened when we shipped to Brazil. I could be Wong.
But, that's mytakeonit
|
|
|
Post by porkini on Dec 11, 2020 0:24:08 GMT -5
I wonder how much of an impact COVID has had in Brazil in regards to Afrezza. The word is Venezuela is pretty COVID bad. Brazil population @ 209.5 million (2018) The governments are using COVID-19 to take the population numbers down.The rich in these countries have live in help. Aren't I susie sunshine. Have to say, I've pondered that, not just Venezuela or Brazil, maybe all those countries with "strongman" type leaders... Oh, and they call me sunny, cuz I'm so bright!
|
|
|
Post by buyitonsale on Dec 11, 2020 16:11:50 GMT -5
|
|
|
Post by akemp3000 on Dec 11, 2020 17:10:15 GMT -5
I am especially looking forward to seeing UTHR's 2021 version of TV commercials promoting Mannkind's drug delivery system. UTHR has the funds to really introduce the world to Technosphere.
|
|
|
Post by sportsrancho on Dec 11, 2020 17:50:04 GMT -5
I am especially looking forward to seeing UTHR's 2021 version of TV commercials promoting Mannkind's drug delivery system. UTHR has the funds to really introduce the world to Technosphere. 🤩😘
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 11, 2020 19:16:21 GMT -5
I am especially looking forward to seeing UTHR's 2021 version of TV commercials promoting Mannkind's drug delivery system. UTHR has the funds to really introduce the world to Technosphere. I don't think 30,000 patients is enough for a National TV Campaign.
|
|
|
Post by buyitonsale on Dec 11, 2020 21:12:58 GMT -5
"Tyvaso, if approved by the FDA, would be the first and only therapeutic approved for the treatment of PH-ILD, a condition that afflicts approximately 30,000 people in the United States," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics.
Companies that have the only approved treatment (no competition) do not need to advertise...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 12, 2020 0:57:32 GMT -5
"Tyvaso, if approved by the FDA, would be the first and only therapeutic approved for the treatment of PH-ILD, a condition that afflicts approximately 30,000 people in the United States," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. Companies that have the only approved treatment (no competition) do not need to advertise... They have competition. There are OFF LABEL treatments for PH-ILD. There is no specific indication so this will be a huge deal for UTHR.
|
|
|
Post by buyitonsale on Dec 12, 2020 13:45:15 GMT -5
Tyvaso is already used off label for PH-ILD as well. It was mentioned on one of the recent CCs.
Doctors are aware of the FDA submission and that is why Tyvaso sales keep going up.
Nevertheless, if approved it will be the only one and I believe UTHR as a market leader in PAH space will do very well.
|
|
|
Post by golfeveryday on Dec 12, 2020 16:08:52 GMT -5
We have three events taking place sometime next year. —TreT FDA filing —Sumatriptan Phase 1 —Clofazimine Phase 1 Some speculative plays for next year include: —Tobramycin and/or Dornase Alfa advancement into Phase 1 or announcement(s) stating they will be initiated into Phase 1 in 2022. —Second UT molecule —New partnership —RLS —COVID —International expansion update (India clinical trial, Australia, etc) —Afrezza Peds Phase 3 start date announcement What’s y’all’s thoughts on next year? I believe it will be an exciting year for the company and us shareholders. and updated agreement with UTHR
|
|